Should Radiation Dose Be Personalized in Patients With Localized NSCLC and Actionable Genetic Alterations? Insight From a Multicenter Real-World Study

Objectives: Radiation therapy (RT) is central to the management of unresectable stage I to III NSCLC. However, the impact of actionable genetic driver alterations (AGAs) on locoregional control (LRC) from RT remains uncertain. A retrospective, multicenter real-world study was undertaken to determine...

詳細記述

書誌詳細

主要な著者:	Salman Ashraf, MB BCh BAO, Madeha Khan, FRCR, Nada Naguib, FRCR, Robert Rulach, FRCR, PhD, Katharine Welsh, FRCR, Rebecca Carozzi, MRCP, Ashley Horne, FRCR, Amelia Payne, MRCP, MRes, Sarah Bowen Jones, FRCR, Mary Denholm, FRCR, Georgia Stewart, MB MSc, Ahmed Bedair, FRCR, Colin R. Lindsay, MRCP, PhD, Stephen Harrow, FRCR, PhD, Corinne Faivre-Finn, FRCR, PhD, Jonathan McAleese, FRCR, Gerard G. Hanna, FRCR, PhD, Allan Hackshaw, PhD, Fiona McDonald, FRCR, MD, Gerard M. Walls, FRCR, PhD
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-04-01
シリーズ:	JTO Clinical and Research Reports
主題:	Non-small cell lung cancer Radiation therapy Actionable genetic alterations Mutations Locoregional control
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2666364324001449
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!